Show simple item record

dc.contributor.authorMirinezhad, SK
dc.contributor.authorSomi, MH
dc.contributor.authorSeyednezhad, F
dc.contributor.authorJangjoo, AG
dc.contributor.authorGhojazadeh, M
dc.contributor.authorMohammadzadeh, M
dc.contributor.authorNaseri, AR
dc.contributor.authorNasiri, B
dc.date.accessioned2018-08-26T06:08:32Z
dc.date.available2018-08-26T06:08:32Z
dc.date.issued2013
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/42333
dc.description.abstractAreas of Iran have among the highest incidences of esophageal cancer in the world. Definitive chemo-radiotherapy (DCRT) is used for locally advanced esophageal cancer and for inoperable tumors asan alternative to surgical treatment.This retrospective study was conducted in North- West Iran 2006-2011, including 267 consecutive patients with non-metastatic esophageal cancer. Eligible inoperable patients were treated with DCRT or definitive radiotherapy (DRT) alone. Radiotherapy (RT) was delivered at 1.8-2 Gy/day for five consecutive days in a given week. Chemotherapy (CT) consisted of cisplatin and 5-fluorouracil.The median survival was 12.7 months with 1, 3 and 5 year survival rates of 55%, 18% and 11%, respectively. On univariate analysis, relations with age at diagnosis (p=0.015), N-stage (p=0.04), total dose of RT (p=0.001), fraction (p<0.001), Gap status (p=0.025), chemotherapeutic regimens (P=0.027), and 5-Fu Mg/m2 (P=0.004) were apparent. Comparing DCRT to DRT, there was a significant difference in survival. Multivariate analysis was performed for comparison between DCRT and DRT showed significant association with age group ?65 to <65 (P=0.02; OR: 1.46), the total RT dose (Gy) ?50 to <50 (P=0.01; OR: 0.65) and the fraction group ?25 to <25 (P=<0.001; OR: 0.54).The survival rates of esophageal cancer treated with DCRT in North West of Iran is poor; therefore, early detection and improved treatment methods, with clinical trials are a high priority.
dc.language.isoEnglish
dc.relation.ispartofAsian Pacific journal of cancer prevention : APJCP
dc.subjectAdenocarcinoma
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectCarcinoma, Squamous Cell
dc.subjectChemoradiotherapy
dc.subjectCisplatin
dc.subjectEsophageal Neoplasms
dc.subjectFemale
dc.subjectFluorouracil
dc.subjectFollow-Up Studies
dc.subjectHumans
dc.subjectIran
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectNeoplasm Recurrence, Local
dc.subjectNeoplasm Staging
dc.subjectPrognosis
dc.subjectRetrospective Studies
dc.subjectSurvival Rate
dc.titleSurvival in patients treated with definitive chemo- radiotherapy for non-metastatic esophageal cancer in north- west iran.
dc.typearticle
dc.citation.volume14
dc.citation.issue3
dc.citation.spage1677
dc.citation.epage80
dc.citation.indexPubmed


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record